Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Major depression and treatment response in adolescents with ADHD and substance use disorder.

Warden D, Riggs PD, Min SJ, Mikulich-Gilbertson SK, Tamm L, Trello-Rishel K, Winhusen T.

Drug Alcohol Depend. 2012 Jan 1;120(1-3):214-9. doi: 10.1016/j.drugalcdep.2011.08.001. Epub 2011 Aug 31.

2.

Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.

Pérez de los Cobos J, Siñol N, Pérez V, Trujols J.

Br J Clin Pharmacol. 2014 Feb;77(2):337-56. doi: 10.1111/bcp.12045. Review.

3.

Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations.

Klassen LJ, Bilkey TS, Katzman MA, Chokka P.

Curr Drug Abuse Rev. 2012 Sep;5(3):190-8. Review.

PMID:
22571450
4.
5.

Methylphenidate in Adults with Attention Deficit Hyperactivity Disorder and Substance Use Disorders.

Simon N, Rolland B, Karila L.

Curr Pharm Des. 2015;21(23):3359-66. Review.

PMID:
26088112
6.

The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.

Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.

Ann Clin Psychiatry. 2012 Feb;24(1):23-37. Review.

PMID:
22303520
7.
8.

Pharmacological treatment of attention deficit hyperactivity disorder with co-morbid drug dependence.

Cunill R, Castells X, Tobias A, Capellà D.

J Psychopharmacol. 2015 Jan;29(1):15-23. doi: 10.1177/0269881114544777. Epub 2014 Aug 20. Review.

PMID:
25142405
9.

Attention-deficit/hyperactivity disorder and early-onset substance use disorders.

Wilson JJ, Levin FR.

J Child Adolesc Psychopharmacol. 2005 Oct;15(5):751-63. Review.

PMID:
16262592
10.

Toward quality care in ADHD: defining the goals of treatment.

Rostain A, Jensen PS, Connor DF, Miesle LM, Faraone SV.

J Atten Disord. 2015 Feb;19(2):99-117. doi: 10.1177/1087054712473835. Epub 2013 Feb 19. Review.

PMID:
23422237
11.

ADHD and behavioral disorders: Assessment, management, and an update from DSM-5.

Austerman J.

Cleve Clin J Med. 2015 Nov;82(11 Suppl 1):S2-7. doi: 10.3949/ccjm.82.s1.01. Review.

12.

A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment.

Daviss WB.

J Child Adolesc Psychopharmacol. 2008 Dec;18(6):565-71. doi: 10.1089/cap.2008.032. Review.

13.

Cognitive behavioral therapy for adolescents with ADHD.

Antshel KM, Olszewski AK.

Child Adolesc Psychiatr Clin N Am. 2014 Oct;23(4):825-42. doi: 10.1016/j.chc.2014.05.001. Epub 2014 Aug 1. Review.

PMID:
25220089
14.

The Adolescent Community Reinforcement Approach (A-CRA) as a model paradigm for the management of adolescents with substance use disorders and co-occurring psychiatric disorders.

Godley SH, Smith JE, Passetti LL, Subramaniam G.

Subst Abus. 2014;35(4):352-63. doi: 10.1080/08897077.2014.936993. Review.

PMID:
25035906
15.

Male adolescent substance use disorder and attention-deficit hyperactivity disorder: a review of the literature.

Eme R.

ISRN Addict. 2012 Nov 28;2013:815096. doi: 10.1155/2013/815096. eCollection 2013. Review.

16.

Treatments for co-occurring depression and substance use in young people: a systematic review.

Deady M, Teesson M, Kay-Lambkin FJ.

Curr Drug Abuse Rev. 2014;7(1):3-17. Review.

PMID:
25323123
17.

Adolescent treatment outcomes for comorbid depression and substance misuse: A systematic review and synthesis of the literature.

Babowitch JD, Antshel KM.

J Affect Disord. 2016 Sep 1;201:25-33. doi: 10.1016/j.jad.2016.04.018. Epub 2016 Apr 29. Review.

PMID:
27156096
18.

Targeting the inflammatory pathway as a therapeutic tool for major depression.

Noto C, Rizzo LB, Mansur RB, McIntyre RS, Maes M, Brietzke E.

Neuroimmunomodulation. 2014;21(2-3):131-9. doi: 10.1159/000356549. Epub 2014 Feb 14. Review.

Items per page

Supplemental Content

Write to the Help Desk